Prevention of corneal vascularization

Topical cell-free conditioned media harvested from adipose tissue-derived stem cells promote recovery from corneal epithelial defects caused by chemical burns

Corneal chemical burns can lead to blindness following serious complications. As most of these complications are caused by failure of reepithelization during the acute phase, treatment at this stage is critical. Although there have been some studies on corneal injury recovery using adipose tissue-derived stem cells (ADSCs), none has reported the effect of topical cell-free conditioned culture media (CM) derived from ADSCs on corneal epithelial regeneration. Here, the best conditions for CM were selected and used for in vitro and in vivo experiments. Corneal burn in rats was induced using 100% alcohol. The chosen CM was administered to corneal burn rats (CM-treated [CT] group) four times a day for three days and this group was compared with the normal control and corneal burn (CB) groups. Biomicroscopic fluorescence images and the actual physical corneas were taken over time and used for analysis. mRNA levels of hepatocyte growth factor and epidermal growth factor (EGF) were significantly increased, whereas those of vascular endothelial growth factor, interleukin (IL)-1β, IL-6, IL-10, and matrix metalloproteinase-9 were significantly decreased in the CT group compared with those in the CB group. The numbers of proliferating cell nuclear antigen- and zonular occludens-1-positive cells in the CT group were significantly higher than those in the CB group. The macrophage-infiltrating corneas in the CT group expressed significantly more of the M2 marker arginase than corneas in the CB group. Optimal CM (× 0.5 concentration) treatment significantly accelerated the migration of corneal epithelial cells and induced upregulation of the expression of IL-6, EGF, and C-X-C chemokine receptor type 4 mRNAs. Overall, in this study, topical administration of cell-free CM promoted regeneration of the corneal epithelium after induction of chemical burns.

Therapeutic approaches for corneal neovascularization

Angiogenesis refers to new blood vessels that originate from pre-existing vascular structures. Corneal neovascularization which can lead to compromised visual acuity occurs in a wide variety of corneal pathologies. A large subset of measures has been advocated to prevent and/or treat corneal neovascularization with varying degrees of success. These approaches include topical corticosteroid administration, laser treatment, cautery, and fine needle diathermy. Since the imbalance between proangiogenic agents and antiangiogenic agents primarily mediate the process of corneal neovascularization, recent therapies are intended to disrupt the different steps in the synthesis and actions of proangiogenic factors. These approaches, however, are only partially effective and may lead to several side effects. The aim of this article is to review the most relevant treatments for corneal neovascularization available so far.

Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes

Introduction. Corneal neovessels are a major risk factor for corneal graft rejection, due to the loss of the immune privilege. The purpose of this study is to evaluate the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovascularization. Material and Methods. This is a prospective study that included 25 eyes of 22 patients with deep corneal neovessels, treated with intrastromal injections of bevacizumab. Results. The average age of patients was 31 years ranging from 16 to 44 years. The causes of neovascularization were dominated by herpetic keratitis (10 cases). The evolution was marked by complete regress of neovessels in 16 patients, partial regress in 6 cases, and reduced opacity and improved visual acuity in 5 patients. No side effects were noted. Discussion. Short-term results demonstrated the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovessels. It may be an option or a complement to other useful treatments in stabilizing or improving vision. Conclusion. Bevacizumab is an effective additional treatment for the improvement of corneal transplants prognosis with preoperative corneal neovascularization.

[Management of corneal neovascularization prior to corneal transplantation: Report of 112 cases]

INTRODUCTION

The avascular nature of the cornea results from a balance between angiogenic factors and anti-angiogenic factors. Under pathological conditions, this homeostasis can be disturbed, resulting in the onset of corneal neovascularization. The purpose of our study was to report our experience in the management of corneal neovascularization prior to keratoplasty.

MATERIALS AND METHODS

This is a prospective study of 112 patients with corneal neovascularization and candidates for possible corneal transplant.

RESULTS

The average age of patients was 38 years, ranging from 15 to 72 years. The etiologies of neovascularization were dominated by ocular trauma (26.8 %). In total, 48.33 % of patients had superficial neovascularization, 18.52 % moderately deep and 33.2 % deep neovascularization. All patients received topical corticosteroids, 29.4 % received subconjunctival injections of bevacizumab, and 22.32 % intrastromal bevacizumab injections. Clinical course was marked by a decrease in the percentage of corneal neovascularization compared to the total corneal surface area, from 45 % (between 16 and 82 %) to 28 % (between 0 and 69 %) at Day 120. There was no statistically significant improvement in visual acuity.

DISCUSSION

Corneal neovascularization is a major risk factor for graft rejection; its management is crucial prior to every keratoplasty.

CONCLUSION

Corneal neovascularization can lead to increased risk of graft rejection. Proper management increases the success rate of penetrating keratoplasty.

Mesenchymal stem cells improve healing of the cornea after alkali injury

PURPOSE

To evaluate the efficacy of mesenchymal stem cells (MSCs) to ameliorate the consequences of corneal alkali injuries.

METHODS

Corneal alkali injuries were created in 30 rabbit eyes. The MSC group (n = 15) were treated with intrastromal and subconjunctival injections of phosphate-buffered saline (PBS) containing 2 × 10(6) MSCs and topical application. The control group (n = 15) was treated with PBS by the same applications forms. Drops of standard treatment (ascorbate 10 %, citrate 10 %, tobramycin, dexamethasone, Cyclogyl) were instilled for 2 weeks. Rabbits underwent slit-lamp examination, fluorescein staining, photography, and were evaluated for corneal neovascularization, opacification, and epithelial defects. Tear secretion and IOP were also evaluated. Furthermore, the concentration of Serumglutamic-pyruvic transaminase (SGPT) and vascular endothelial factor (VEGF) were measured. Immunohistochemistry was also performed for a-SMA and Ki-67.

RESULTS

Eyes treated with MSCs showed better recovery. The mean neovascularized area was significantly smaller in the MSC group (p < 0.05). A significant difference in the degree of corneal opacification and re-epithelialization was also observed, as well as the IOP at 21 and 28 posttraumatic days (p < 0.05). Histology showed that MSCs resulted in almost normal architecture of eye tissues. After the MSCs infusion, SGPT and VEGF levels in cornea were significantly reduced. Immunohistochemistry demonstrated a reduction of a-SMA in the MSC group with higher mitotic-regenerative activity with the presence of Ki67.

CONCLUSIONS

Our study represents a first step in understanding the possibilities of the MSC approach to treatment of alkali injuries of the cornea and shows that such an approach improves clinical outcomes and leads to better prognosis.

Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits

PURPOSE

The aim was to compare the effect of subconjunctival injections of ranibizumab and bevacizumab on corneal neovascularization (NV) in rabbits.

METHODS

NV was induced by placing a suture at the corneal periphery of rabbits (n = 30 eyes). Immediately after suturing, the rabbits were divided into 3 groups and 7 days later administered subconjunctival injections of ranibizumab (Lucentis; 0.5 mg/0.05 mL), bevacizumab (Avastin; 5 mg/0.05 mL), or normal saline (control), respectively. The time-course photographs to measure the area of the corneal NV were obtained on days 7, 10, and 14 after suture placement. Histological examination and immunohistochemical analysis for the vascular endothelial growth factor and CD34 were performed.

RESULTS

Analysis of digital photographs showed that there was less corneal NV in the ranibizumab- and bevacizumab-treated eyes than in the control eyes (P = 0.012, 1-way analysis of variance); however, no significant differences between the ranibizumab- and bevacizumab-treated eyes were seen. In addition, there was less staining for vascular endothelial growth factor and CD34 in the corneas from the ranibizumab-treated eyes and bevacizumab-treated eyes than in the control eyes, and there were no significant differences in the staining intensity between the ranibizumab- and bevacizumab-treated eyes. Subconjunctival ranibizumab and bevacizumab injections were not associated with any complications during observations.

CONCLUSIONS

Subconjunctival administrations of ranibizumab or bevacizumab inhibit corneal NV in rabbits and have equivalent effects on it.

Inhibition of blood vessel formation by a chondrocyte-derived extracellular matrix

In this study, the chondrocyte-derived extracellular matrix (CECM) was evaluated for its activity to inhibit vessel invasion in vitro and in vivo. Human umbilical vein endothelial cells (HUVECs) and rabbit chondrocytes were plated on a bio-membrane made of CECM or human amniotic membrane (HAM). The adhesion, proliferation, and tube formation activity of HUVECs and chondrocytes were examined. The CECM and HAM powders were then mixed individually in Matrigel and injected subcutaneously into nude mice to examine vessel invasion in vivo after 1 week. Finally, a rabbit model of corneal neovascularization (NV) was induced by 3-point sutures in the upper cornea, and CECM and HAM membranes were implanted onto the corneal surface at day 5 after suture injury. The rabbits were sacrificed at 7 days after transplantation and the histopathological analysis was performed. The adhesion and proliferation of HUVECs were more efficient on the HAM than on the CECM membrane. However, chondrocytes on each membrane showed an opposite result being more efficient on the CECM membrane. The vessel invasion in vivo also occurred more deeply and intensively in Matrigel containing HAM than in the one containing CECM. In the rabbit NV model, CECM efficiently inhibited the neovessels formation and histological remodeling in the injured cornea. In summary, our findings suggest that CECM, an integral cartilage ECM composite, shows an inhibitory effect on vessel invasion both in vitro and in vivo, and could be a useful tool in a variety of biological and therapeutic applications including the prevention of neovascularization after cornea injury.

Inhibition of corneal neovascularization in rats by systemic administration of sorafenib

PURPOSE

To evaluate the effect of orally administered sorafenib on corneal neovascularization in rat models.

METHODS

In male Sprague-Dawley rats, a silver nitrate applicator was placed on the central cornea in both eyes to elicit angiogenesis. Rats were divided into 3 groups, the control group and the 2 sorafenib-treated groups (low dose, 30 mg · kg(-1) · day(-1); high dose, 60 mg · kg(-1) · day(-1)). The area of corneal neovascularization was measured by image analysis. Vascular endothelial growth factor receptor 2 (VEGFR2) messenger RNA expression was measured in rat corneas by reverse transcription-polymerase chain reaction, and the expression of phosphorylated extracellular signal-regulated kinase (ERK) was measured by Western blot analysis 1 week after cauterization.

RESULTS

The area of corneal neovascularization was significantly reduced by 44% in the 30 mg · kg(-1) · day(-1) group and by 66% in the 60 mg · kg(-1) · day(-1) group, compared with the control group (P = 0.014 and P < 0.0001). Corneal VEGFR2 messenger RNA expression was higher in the control group than in the sorafenib-treated groups. The expression of phosphorylated ERK in rat corneas was suppressed in the sorafenib-treated groups but not in the control group.

CONCLUSIONS

Oral administration of a multikinase inhibitor (sorafenib) significantly reduced the development of experimental corneal neovascularization in a dose-dependent manner. This inhibitory effect is probably related to the suppression of ERK phosphorylation by sorafenib.

Treatments for corneal neovascularization: a review

Corneal neovascularization (CNV) may be a physiological response to various stimuli, but a chronic and persistent upregulation of neoangiogenesis can result in pathological CNV. Pathological blood vessels are immature and lack structural integrity, predisposing the cornea to lipid exudation, inflammation, and scarring. CNV can therefore become a potentially blinding condition. In this review, we frame CNV in an epidemiological perspective, consider risk factors for CNV, provide an overview of CNV pathogenesis, and consider the impact of CNV on corneal transplantation. We consider treatments that are of largely historical interest, before reviewing contemporary medical and surgical treatments. Within medical treatments, we report on steroids, nonsteroidal anti-inflammatory agents, antivascular endothelial growth factor agents, and cyclosporine. Within surgical treatments, we report on the use of lasers, photodynamic therapy, superficial keratectomy, and diathermy/cautery-based treatments.

Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin)

PURPOSE

To evaluate the effect of subconjunctival bevacizumab (Avastin) administration on corneal neovascularization (NV) in rabbits.

METHODS

NV was induced by placing a suture at the corneal periphery of the right eye of 20 rabbits. Immediately after suturing and again 1 week later, rabbits were divided into 2 groups and administered a subconjunctival injection of normal saline (control) or bevacizumab (Avastin; 5 mg/0.2 mL), respectively. On day 14, digital photographs of the cornea were taken and analyzed to determine the area of the cornea covered by NV. In addition, immunohistochemical analysis was used to determine CD31 and vascular endothelial growth factor (VEGF) expression in corneal tissue.

RESULTS

Analysis of digital photographs showed that there was less corneal NV in bevacizumab-treated eyes than in controls (P < 0.001, Mann-Whitney U test). In addition, there was less staining for VEGF and CD31 in corneas from bevacizumab-treated eyes than in control eyes. Subconjunctival bevacizumab injections were not associated with any complications during observation.

CONCLUSIONS

Subconjunctival bevacizumab administration decreased suture-induced corneal neovascularization in rabbits.

Comparison of Yellow Dye, Continuous Wave Nd=YAG, and Argon Green Laser on Experimentally Induced Corneal Neovascularization

BACKGROUND

Corneal neovascularization is generally undesirable because it can lead to corneal scarring, lipid deposits, and corneal graft failure. To eliminate these vessels, several techniques are available including laser photocoagulation.

METHODS

This prospective study was designed to compare the effectiveness of three laser wavelengths (continuous wave Nd:YAG, 1064 nm; argon green 514 nm; and yellow dye, 570 nm) to obliterate experimentally induced corneal neovascularization in the rabbit. Corneal vascularization was created in 12 rabbits by placing 7-0 silk sutures through two quadrants of the cornea. Once neovascularization was complete, the suture was removed and one of the three lasers was applied to occlude vessels at one of the neovascular sites. The other site was used as a control.

RESULTS

The yellow wavelength, when compared with the green required fewer exposures to occlude corneal vessels. At no time during observation was any laser more effective than the control. In the continuous wave Nd:YAG group, tissue necrosis was needed to achieve closure of vessels.

CONCLUSIONS

Yellow and green laser light are equally effective in eliminating the corneal vessels. Continuous wave Nd:YAG, as used here, appears to be a poor choice.

Phthalocyanine mediated photodynamic thrombosis of experimental corneal neovascularization: effect of phthalocyanine dose and irradiation onset time on vascular occlusion rate

The aim of this study was to evaluate the possible influence of phthalocyanine dose and of time interval between phthalocyanine injection and irradiation commencement on the rate of experimental corneal neovascularization photodynamic thrombosis in albino rabbits. New corneal vessels were irradiated with a diode laser (670 nm, 2 mW) after the intravenous injection of chloroaluminum sulfonated phthalocyanine. Different animals were irradiated either 5 min after the injection of different phthalocyanine doses (3, 6, 8, 12, or 14 mg/kg), or at different times (5 min, 24 h, or 58 h) after a standard phthalocyanine dose (3 mg/kg) injection. Irradiation time necessary for vascular occlusion was recorded. Decrease of phthalocyanine dose as well as delay of irradiation onset resulted in a statistically significant increase of irradiation time. Electron and light histological examination revealed platelet thrombi inside irradiated corneal new vessels. Damage in the vascular endothelial cell membrane and in intercellular contact structure was noted, leading to disorganization of the endothelial cells layer and death of most endothelial cells. These results indicate that both early commencement of irradiation after phthalocyanine injection and phthalocyanine dose increase accelerate the rate of phthalocyanine mediated corneal neovascularization photodynamic thrombosis. Thrombosis seems to result from photochemically induced vascular endothelial cell damage.

Laser photocoagulation of experimental corneal stromal vascularization. Efficacy and histopathology

BACKGROUND

Conventional treatment of corneal stromal vascularization is often inadequate. The authors developed a rabbit model of corneal stromal vascularization, treated it with laser photocoagulation, and then studied the histopathology.

METHODS

A reproducible model of corneal stromal vascularization was developed in albino rabbits by injecting sodium hydroxide into the corneal stroma. Corneal stromal vascularization was produced in both eyes of 13 rabbits, and treated after stabilization at 5 weeks with 577-nm yellow dye laser in 1 eye of each rabbit. Seven rabbits were followed for 6 months with corneal angiography and photography, and the corneal stromal vascularization quantified with a grid. The other 6 rabbits were killed at 1, 4, 8, 24, 48 hours, and 6 days after laser photocoagulation and examined by light and transmission electron microscopy.

RESULTS

Stable corneal stromal vascularization was observed in the anterior and midstroma for at least 6 months in the model. Laser photocoagulation reduced corneal stromal vascularization significantly compared with the controls (P < or = 0.05), resulting in 40.7% +/- 5.0%, 45.3% +/- 3.3%, and 34.9% +/- 5.2% (mean +/- standard error of the mean) reduction at 2, 4, and 6 months, respectively. Maximum inflammatory cell infiltrates were detected at 8 hours after laser photocoagulation, which diminished markedly at 6 days. The stroma of unlasered eyes showed no inflammatory cells and considerably more patent blood vessels than the lasered eyes. In the lasered eyes, transmission electron microscopy showed damaged vascular endothelial cells, extravasated erythrocytes, haphazardly arranged collagen fibrils, thrombus formation, and ghost vessels in the stroma. No damage was observed in the deep corneal stroma or endothelium in the lasered eyes.

CONCLUSION

Laser photocoagulation is effective in reducing corneal stromal vascularization in this model for at least 6 months. It does not damage the deeper stroma or endothelium.

Argon laser treatment of lipid keratopathy

Sixty-three cases of vascularised lipid keratopathy were treated with the argon laser to occlude feeder vessels which had been identified by fluorescein angiography. There was a reduction in extent in 62% and density in 49%. Visual acuity was improved in 48%. Six patients had keratoplasties shortly after treatment, none of which showed graft rejection. Minor complications included temporary haemorrhage into the cornea and iris atrophy. A more serious problem was severe corneal thinning after resorption of lipid. The patients had to be carefully followed up and maintained on a low dose of topical steroid.

Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty

Corneal argon laser photocoagulation (CALP) was used in 13 patients to treat deep stromal vascular ingrowth. Eight patients had undergone successful penetrating keratoplasty but had developed deep stromal vessels into the graft associated with signs of graft rejection, which did not improve with steroid treatment alone (group 1). After CALP, there was marked regression of the neovascularization with reversal of graft rejection in all eyes. Three additional patients with vascularized corneas, referred for penetrating keratoplasty, underwent CALP preoperatively with obliteration of the vessels (group 2). Two of these patients have since undergone keratoplasty and, in both, the grafts have remained avascular and clear over a 21-month follow-up. Two other patients with corneal injury and progressive corneal opacification and vascularization have also been treated with CALP (group 3). CALP may be a useful adjunct in the treatment of corneal neovascularization. Further clinical studies are needed to define its exact role.

Laser interactions with the cornea

Principles of laser-tissue interactions in the eye are reviewed. Corneal structure and function are summarized, with particular regard for features related to laser treatment. A summary of argon and carbon dioxide laser techniques in the cornea is presented, followed by a review of studies on corneal response to ultraviolet radiation. A detailed description is then given of the characteristics of excimer laser tissue ablation. Potential applications of this process in corneal and keratorefractive surgery are reviewed.

Treatment of lipid keratopathy with the argon laser

Twenty-two patients with lipid keratopathy were treated with argon laser photocoagulation to the feeder vessels. Two were grafted just over a week after treatment and the corneal discs examined histologically. The remainder of the patients were followed up for a least a year. In 6 cases the visual acuity improved, in 3 deteriorated, and in 10 did not change. The density and extent of the lipid deposition were diminished in 50% of cases. The commonest complications were bleeding into the lipid keratopathy and iris damage. The only serious problem was a disciform type of lipid keratopathy that flared up after treatment. Suggestions are made on improvements in the technique of laser application.

[Regression of corneal neovascularization by laser treatment? (author's transl)]

The corneal neovascularization produced by NaOH burns was examined in two groups of pigmented rabbits following laser treatment. The treatment was carried out with energy level 500 mW, spot diameter 200 micron, and exposure time 1 s throughout. In the first group, a single newly formed vessel was coagulated in each case. Subsequent fluorescein angiography invariably showed an incomplete occlusion of the vessel. In the second group, we coagulated a section of the neovascularization network at its origin in the corneal limbus. After 48 h, fluorescein perfusion was once again observed, but the vessels were predominantly finer than before. Fluorescence microscopy revealed a rich neovascularization of the more superficial layers of the corneal stroma. To be successful, laser treatment must involve both supplying and draining vessels.